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Abstract Surface plasmon resonance analysis shows that the
carboxy-terminal domain of Grp94 (Grp94-CT, residues 518^
803) physically interacts with the catalytic subunit of protein
kinase CK2 (CK2K) under non-stressed conditions. A KD of
4U1037 was determined for this binding. Heparin competed
with Grp94-CT for binding to CK2K. CK2L also inhibited the
binding of Grp94-CT to CK2K, and CK2 holoenzyme recon-
stituted in vitro was unable to bind Grp94-CT. The use of CK2K
mutants made it possible to map the Grp94-CT binding site to
the four lysine stretch (residues 74^77) present in helix C of
CK2K. Grp94-CT stimulated the activity of CK2K wild-type but
was ineffective on the CK2K K74^77A mutant. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Glucose-regulated protein of 94 kDa (Grp94) is the endo-
plasmic resident member of the 90 kDa heat shock protein
(hsp90) family sharing 49% identity with hsp90 for human
proteins, with major di¡erences in their C-terminal domain
[1]. Grp94 is constitutively expressed in all cell types and is
upregulated by di¡erent stress conditions such as low glucose
levels, acidic pH, viral infection and di¡erent treatments such
as reducing agents, ionophores or tunicamycin [2]. Although
Grp94 is mainly an endoplasmic reticulum resident protein it
has also been found associated with cytoplasmic proteins and
it is a substrate for cytosolic proteases [3^5] suggesting that it
may also exist either as a cytoplasmic protein or as a trans-
membrane protein with the carboxy-terminus on the cytosolic
face. Furthermore, Grp94 has been detected on the cell sur-
face of cultured muscle and tumour cells [6,7]. The physiolog-
ical role of Grp94 is still under discussion but it has been
implicated, as a molecular chaperone, in the folding of secre-
tory and membrane proteins. It seems to be preferentially
implicated in the folding of advanced folding intermediates
or of incompletely assembled proteins [8]. The C-terminal do-
main of Grp94 contains a peptide binding site [9] and prevents
in vitro the aggregation of the catalytic K subunit of protein
kinase CK2 [10].
Protein kinase CK2 is a constitutively active enzyme with
unknown regulation pathway, which is overexpressed in tu-
mour cell lines and in proliferating tissues (for review see [11]).
The catalytic subunit of CK2 (CK2K) is active either alone or
when forming the heterotetrameric structure with the regula-
tory L subunit (CK2L). CK2 has been implicated in the phos-
phorylation of a broad range of proteins involved in multiple
cellular functions (for a review see [12]). The holoenzyme
(K2L2) seems to be the most abundant form of the enzyme
but it has been shown that the catalytic subunit can also exist
either as a free subunit or associated with other cellular pro-
teins, and these forms may play di¡erent roles than the holo-
enzyme [13]. Since Grp94 can interact with CK2 under non-
stressed conditions, we hypothesise that Grp94 could play a
role in the folding of protein kinase CK2 and in maintaining
the pool of free CK2K in a competent state. In this work, we
tried to de¢ne the regions in CK2K involved in its interaction
with the carboxy-terminal domain of Grp94, and the possible
consequences of this interaction on CK2K activity.
2. Materials and methods
2.1. Chemicals
[Q-32P]ATP was from Amersham. Ni2-nitrilotriacetic acid agarose
was from Qiagen. Secondary antibodies were from Bio-Rad and all
other chemicals were from Sigma. Polyclonal antibody against CK2K
(residues 70^89) was from StressGen. Polyclonal antibodies against C-
terminal Grp94, CK2L and CK2K were raised by immunisation of
rabbits with recombinant proteins.
2.2. Expression and puri¢cation
Human C-terminal Grp94 (Grp94-CT), CK2K and CK2L wild-
type were expressed in Escherichia coli and puri¢ed as described
previously [10]. CK2K mutants (KK74^77A, KK79R80K83A,
KR191K195K198A, KR278K279R280A, Kv2^12, Kv2^18, KK77A)
were expressed in E. coli and puri¢ed as described previously [14].
CK2K from Zea mays [15] and human CK2K’ [16] were expressed
and puri¢ed according to the procedures described previously.
2.3. Surface plasmon resonance (SPR) analysis
BIAcore X system (BIAcore) was used to detect the interactions.
CK2K, CK2L or C-terminal Grp94 were covalently linked to a sensor
chip CM5 (BIAcore) using amine coupling chemistry [17]. In the case
of C-terminal Grp94 the coupling was done in the presence of 10 mM
dithiothreitol to ensure a homogeneous monomeric preparation of
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C-terminal Grp94. C-terminal Grp94, CK2L, CK2K or di¡erent
CK2K mutants (see Table 1 for details) were injected over the surface
with a £ow rate of 10 Wl/min in running bu¡er HBS (10 mM HEPES
pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) at
25‡C. After injection HBS replaced the protein solutions in a contin-
uous £ow rate of 10 Wl/min. All samples were run simultaneously over
a £ow cell containing a blank surface. The kinetic data were calcu-
lated using the SPR kinetic evaluation software BIAevaluation 3.0
(BIAcore).
2.4. Protein and phosphorylation assays
Protein concentration in the samples was determined by the Brad-
ford method [18] using bovine serum albumin as standard. Protein
kinase CK2 activity was assayed as described previously [14] using
0.1 mM of speci¢c peptide (RRRAADSDDDDD) and 125 WM
[Q-32P]ATP as substrates (speci¢c activity 300 cpm/pmol).
3. Results
3.1. SPR analysis of CK2K/Grp94-CT interaction
The interaction between CK2K and Grp94-CT, the latter
covalently linked to a sensor chip CM5, was checked using
the SPR technique (Fig. 1A). To quantitatively measure the
interaction, di¡erent concentrations of CK2K (110, 220, 550,
1100, and 2200 nM) were injected on the Grp94-CT chip. An
association constant of 4U1037 M was estimated from the
data of the binding. Interaction between CK2K covalently
linked to a sensor chip CM5 and soluble Grp94-CT was
also observed (data not shown). Binding to the Grp94-CT
chip was also observed when human CK2KP or Z. mays
CK2K were tested (Fig. 1B shows a representative interaction
with Z. mays CK2K. A similar signal was detected for
CK2KP). Human CK2KP is 70% homologous to CK2K but
lacks the 61 amino acids in the carboxy-terminal part of the
protein. Comparison of CK2K from Z. mays with human
CK2K also gave a homology of 70% and again the former
lacks 59 amino acids in the carboxy-terminal part of the pro-
tein. The fact that both proteins bind to Grp94-CT would
indicate that the carboxy-terminal part of CK2K is not in-
volved in their interaction.
Protein kinase CK2 from porcine testis has been reported
to bind hsp90 through a region located between residues 62
and 83 [19]. This region contains a polylysine stretch
(74KKKKIKREIK83) that has been described to be one of
the most peculiar parts of CK2K. This cluster plays a prom-
inent role in heparin binding, downregulation by CK2L, and
substrate recognition [14]. To determine if this region of
CK2K was also involved in the binding to Grp94-CT, di¡erent
CK2K mutants were checked for interaction (see Table 1).
Fig. 2A shows the sensorgram for the CK2K K74^77A mu-
tant, where a complete inhibition of the interaction can be
observed when lysines in this region were mutated to alanines.
This is a speci¢c characteristic since, as reported earlier
[20,14], this mutant is still able to interact both physically
and functionally with the CK2L subunit.
Next, we tested the binding of the mutant CK2K
K79R80K83A that contains the mutations on the second
part of the basic stretch. As shown in Fig. 2B this mutant
was still able to bind Grp94-CT and the interaction was con-
centration dependent. It is likely that the second half of the
basic stretch has also some contribution to the interaction
because the shapes of the sensorgrams obtained were slightly
di¡erent from those of CK2K wt. On the other hand, the
CK2K K77A mutant was able to bind Grp94-CT with a ki-
netic constant similar to that of CK2K wt (data not shown).
Residues R191, R195 and K198 in CK2K are also implicated
in heparin binding and in the downregulation by CK2L. How-
ever, mutation of these residues did not a¡ect the binding of
CK2K to Grp94-CT (see Table 1).
To con¢rm the implication of the polylysine stretch on the
interaction between CK2K and Grp94-CT, CK2K plus di¡er-
ent concentrations of heparin were injected on the Grp94-CT
chip. As shown in Fig. 2C, the binding was completely pre-
vented even at concentrations of heparin as low as 1 nM.
Crystallographic data [21] have shown that the N-terminal
region of CK2K makes extensive contacts with the lysine clus-
ter and with the activation loop. In order to explore if this
Table 1
Summary of proteins checked for interaction on Grp94-CT chip
Grp94-CT chip
K wt +++
KP wt ++
K Z. mays ++
KK74^77A 3
KK79R80K83A +
KR278K279R280A +
Kv2^12 ++
Kv2^18 ++
KR191R195K198A +
KK77A +
K2L2 holoenzyme 3
L wt 3
The symbols indicate interaction (+) or no interaction (3) and the
strength of the binding.
Fig. 1. Interaction of the K subunit of protein kinase CK2 with
Grp94-CT by SPR. Representative sensorgrams obtained by injec-
tion of 35 Wl of sample at a £ow rate of 10 Wl/min over a sensor
surface containing 780 resonance units (RU) of immobilised Grp94-
CT. The response obtained with a control sensor surface (without
protein immobilised) was subtracted from each sensorgram. The re-
sponse di¡erence is measured in RU. A: Sensorgrams of injected
CK2K at the indicated concentrations. B: Sensorgrams of injected
CK2K at 40 nM (continuous line) and CK2K from Z. mays (dotted
line) at 100 nM.
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region could in£uence the interaction with Grp94-CT, dele-
tion mutants of the N-terminal region (CK2K v2^12 and
v2^18) were tested. The binding between the mutants and
Grp94-CT had the same association signal as that of CK2K
wt (see Table 1).
Binding between CK2L and Grp94-CT was also tested us-
ing either Grp94-CT or CK2L immobilised on the chip and
injecting the other protein but no interaction was observed
(Fig. 3A). Interestingly, no binding was either detected when
using reconstituted CK2 holoenzyme (K2L2) as a ligand (Fig.
3B).
3.2. CK2 activity assay in the presence of Grp94-CT
In a previous work [10] it was shown that casein phosphor-
ylation by CK2K seemed to be enhanced by Grp94-CT. How-
ever, the fact that Grp94-CT is also a substrate for CK2 [16],
with at least ¢ve putative phosphorylation sites located in its
carboxy-terminal domain, made it di⁄cult to discern if the
increase in activity was due to an activation of casein phos-
phorylation or to a simultaneous phosphorylation of Grp94-
CT. The use of the CK2 speci¢c synthetic peptide substrate
RRRAADSDDDDD made it possible to work at substrate
concentrations 1000-fold higher than those of Grp94-CT,
which minimised the contribution of Grp94-CT phosphoryla-
tion to less than 1% of total. Under these conditions, Grp94-
CT stimulated CK2K wt in a way similar to that caused by
CK2L (Fig. 4), although it required Grp94-CT/CK2K molar
ratios higher than those of CK2L/CK2K. Interestingly, Grp94-
CT was unable to stimulate CK2K K74^77A, whose activity
conversely increased in the presence of CK2L. These data
reinforce the concept that the 74^77 basic stretch in CK2K
is essential for interactions with Grp94-CT.
4. Discussion
The carboxy-terminal domain of Grp94 has been shown to
interact in vitro with CK2K and to protect it against heat-
induced aggregation [10]. In the present study we show that
binding also occurs under non-stressed conditions. Kinetic
analysis of the interaction, by SPR, gave an approximate
equilibrium dissociation constant (KD) of 4U1037 M, a value
comparable to that reported previously for the interaction
between hsp90 and CK2 [19]. Other studies using CK2K sub-
unit as a partner have shown KD values for the association
with either prion protein bPrP [22] or haematopoietic protein
HS1 [17] in the same range of that found for Grp94-CT, with
the exception of transcription factor ATF1, which showed a
Fig. 2. Analysis of the binding site of CK2K to Grp94-CT. Repre-
sentative sensorgrams obtained by injection of 35 Wl of sample at a
£ow rate of 10 Wl/min over a sensor surface containing 780 RU of
immobilised Grp94-CT. The response obtained with a control sensor
surface (without immobilised protein) was subtracted from each sen-
sorgram. A: Sensorgrams of injected CK2K 40 nM (dotted line)
and 1000 nM and 5000 nM of KK74^77A mutant. B: Sensorgrams
of injected CK2K 40 nM (dotted line) and injected CK2K
K79R80K83A mutant 40 and 200 nM (continuous lines). C: Sensor-
grams of injected CK2K (dotted line) and injected CK2K plus two
di¡erent concentrations of heparin (1 and 100 nM).
Fig. 3. Analysis of interaction between CK2 holoenzyme and
Grp94-CT. Representative sensorgrams obtained by injection of
35 Wl of sample at a £ow rate of 10 Wl/min over a sensor surface
containing 780 RU of immobilised Grp94-CT. A: Sensorgrams of
injected CK2K (dotted line) and two di¡erent concentrations of the
holoenzyme (K2L2) reconstituted with CK2K wt or with CK2K
K74^77A mutant (continuous lines). B: Sensorgrams of injected
CK2K (continuous line) and CK2L (dotted line).
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KD of 1.2U1038 [23], similar to that found for CK2L subunit
[17].
The data shown herein demonstrate that the interaction
between Grp94-CT and CK2K takes place through the four
lysine stretch, located at the start of helix C in CK2K, which is
exposed to the solvent in the absence of CK2L [21]. Neither
the C-terminal region nor the N-terminal region of CK2K
seems to be involved in the interaction. The lysine-rich region
was also the proposed site for interaction with hsp90 [19].
However, hsp90 bound to CK2 through an acidic region
(residues 227^249) located in its N-terminal domain. The
C-terminal domain of Grp94 also contains a negatively
charged region (residues 747^803) that could be responsible
for the interaction with CK2K. In fact, comparison of Grp94-
CT and CK2L showed that this C-terminal region contains
a stretch of 15 residues (747LNIDPDAKVEEEPEE761) with
a high homology to the acidic loop of CK2L
(54LDLEPDEELEDNPNQ68) which could be the interacting
domain of Grp94 with CK2K. Interestingly, Grp94-CT bound
neither the CK2 holoenzyme nor the free CK2L subunit. It is
likely that the interacting regions between CK2K and Grp94-
CT are buried in the CK2 holoenzyme and, consequently, not
available for interaction. The four lysine stretch of CK2K is
inserted in a putative nuclear localisation signal (PVKKKKI)
which would be masked by the interaction with the C-terminal
domain of Grp94. Thus, the subcellular localisation of CK2K
could be in£uenced by the interaction with Grp94.
It has been reported that the C-terminal domain of CK2L
subunit also interacts with CK2K. This binding does not in-
volve the basic cluster of CK2K but the upper lobe of this
subunit, and stimulates its catalytic activity [14]. Our present
data con¢rm the existence on CK2K of CK2L binding sites
distinct from those interacting with Grp94-CT since CK2L but
not Grp94-CT activates the CK2K K74^77A mutant, which is
unable to stably interact with Grp94-CT. Nonetheless, inter-
action with Grp94-CT does not downregulate CK2K catalytic
e⁄ciency on the peptide substrate model, as caused by its
interaction with the acidic loop of CK2L. In fact, association
with Grp94-CT not only maintained CK2K in an active form
but also stimulated its activity, suggesting a parallel action of
Grp94-CT and CK2L on CK2K.
It has been shown that CK2L exerts a protective role on
CK2K against high temperature, acting as a chaperone-like
molecule [23], thus Grp94 may keep CK2K in an activated
and correctly folded form in solution until it can interact
with CK2L to form the holoenzyme, which results in a de-
crease in its binding to Grp94-CT. This fact implies a possible
role of Grp94 in the folding of CK2K and assembling of the
holoenzyme. Alternatively, binding to Grp94 may hold CK2K
in a competent state to bind other cellular partners. Further-
more the data obtained with CK2K from Z. mays suggest that
interaction with Grp94-CT may play an important role since
it is conserved in animals and plants.
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